Astellas Pharma
Astellas Pharma Inc. is a Japanese pharmaceutical enterprise that discovers, develops, manufactures, and commercializes prescription pharmaceuticals worldwide. The company concentrates its operational activities across key therapeutic focus areas including oncology, urology, immunology, nephrology, and gene therapy. Its commercial product portfolio includes flagship prescription medicines such as Xtandi for prostate cancer, Padcev for urothelial cancer, Xospata for leukemia, and Veozah for menopause symptoms. Principal revenue drivers consist of worldwide commercial sales of proprietary prescription biopharmaceuticals, alongside strategic research licensing agreements and distribution partnerships. Astellas Pharma serves broad global end markets encompassing hospital procurement bodies, retail and specialty pharmacy chains, healthcare providers, and patients across Japan, the Americas, Europe, and Asia. The enterprise maintains a leading market position as one of Japan's premier pharmaceutical manufacturers with a major global footprint in targeted oncology treatments. Headquartered in Tokyo, Japan, the company's common stock is publicly traded on the Tokyo Stock Exchange under the ticker code 4503.
89 of the funds FundTelligence covers report a position in Astellas Pharma.
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 89
Funds holding Astellas Pharma
- DWS Invest CROCI Japan — DWS · 3.32 % (full portfolio disclosed, June 2026)
- DWS Invest CROCI Sectors Plus — DWS · 3.15 % (full portfolio disclosed, June 2026)
- Fondsfinans Global Helse — Fondsfinans · 2.47 % (full portfolio disclosed, October 2026)
- DWS Invest CROCI Global Dividends — DWS · 1.83 % (full portfolio disclosed, June 2026)
- Danske Invest Japan Index Restricted — Danske Invest · 1.0 % (full portfolio disclosed, July 2026)
- DWS Invest CROCI World Value — DWS · 1.0 % (full portfolio disclosed, June 2026)
- Storebrand Japan — Storebrand · 0.82 % (full portfolio disclosed, October 2026)
- Nordea Japan — Nordea Funds · 0.78 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 89 funds holding it.